Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Huntington's disease

This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

AbbVie has decided to exit its existing partnership with Voyager Therapeutics for the development of gene therapies for Alzheimer’s and Parkinson’s disease. ... This included handing back the rights to a number of candidates, including a potential

Latest news

More from news
Approximately 6 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    We need to fast-track new treatments. As of last year, there are over 100 treatments in clinical trials for Alzheimer’s disease. ... The Dementia Consortium funds research into novel targets and treatments for dementia including Alzheimer’s disease,

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    to learn from its own mistakes with therapies for Huntington’s disease and also haemophilia. ... Increasingly factored into this equation is competition from companies following Bluebird into beta thalassemia and sickle cell disease.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease. ... It’s hoped it could be a big step in treatment for the genetically-inherited and rare wasting disease.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • uniQure appoints chief executive officer uniQure appoints chief executive officer

    This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. ... for congestive heart failure and Huntington's disease into the clinic.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....

Quick links